Evidence map›Paper›PMID 38627147›Full record

ArticleVaccine2024

Antibody kinetics between birth and three months of life in healthy infants with natural exposure to Group B streptococcus: A UK cohort study.

Konstantinos Karampatsas, Tom Hall, Merryn Voysey, Clara Carreras-Abad, Madeleine Cochet, Laxmee Ramkhelawon, Elisabeth Peregrine, Nick Andrews, Paul T Heath, Kirsty Le Doare

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Review
  2. Maternal and Newborn Group BOpen forum infectious diseases · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Konstantinos KarampatsasCentre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom. Electronic address: kkarampa@sgul.ac.uk.
Tom HallCentre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom.
Merryn VoyseyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Clara Carreras-AbadCentre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom.
Madeleine CochetCentre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom.
Laxmee RamkhelawonCentre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom.
Elisabeth PeregrineDepartment of Obstetrics and Gynaecology, Kingston Hospital NHS Foundation Trust, London, United Kingdom.
Nick AndrewsUK Health Security Agency, London, United Kingdom.
Paul T HeathCentre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom.
Kirsty Le DoareCentre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom; Pathogen Immunology Group, UK Health Security Agency, Porton Down, United Kingdom; Makerere University Johns Hopkins University, Kampala, Uganda.
St George's, University of London · GBKingston Hospital · GBUK Health Security Agency · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCapsular polysaccharide (CPS) serotype-specific Immunoglobulin G (IgG) in cord blood has been proposed as a correlate of protection against invasive Group B Streptococcus (iGBS) disease. Although protective levels are required in infants throughout the window of vulnerability up to 3 months of age, little is known regarding the kinetics of GBS-specific IgG over this period.

methodsWe enrolled 33 healthy infants born to mothers colonized with GBS. We collected cord blood and infant blood samples either at one (21-35 days), two (49-63 days), or three months of age (77-91 days). We measured GBS serotype-specific CPS IgG concentrations and calculated the decay rate using a mixed-effects model. We further explored whether the antibody kinetics were affected by common maternal and infant factors and estimated the correlation between IgG concentration at birth and one, two, and three months of age.

resultsThe half-life estimate of IgG concentration for homologous and non-homologous GBS serotypes in paired samples with detectable IgG levels at both time points was 27.4 (95 % CI: 23.5-32.9) days. The decay rate did not vary by maternal age (p = 0.7), ethnicity (p = 0.1), gravida (p = 0.1), gestation (p = 0.7), and infant sex (p = 0.1). Predicted IgG titres above the assay lower limit of quantification on day 30 strongly correlated with titres at birth (Spearman correlation coefficient 0.71 [95 % CI: 0.60-0.80]).

conclusionOur results provide a basis for future investigations into the use of antibody kinetics in defining a serocorrelate of protection against late-onset iGBS disease.

Indexed as

Antibodies, BacterialImmunoglobulin GStreptococcal InfectionsStreptococcus agalactiaeAdultCohort StudiesFemaleFetal BloodHumansImmunity, Maternally-AcquiredInfantInfant, NewbornMalePregnancySerogroupUnited KingdomAntibodies, BacterialImmunoglobulin GAntibody kineticsCorrelate of ProtectionGroup B streptococcusMaternal vaccination

Identifiers

PMID38627147
PMCPMC11514126
OpenAlexW4394823855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.